Molecular Cancer Therapeutics: Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

Published Online March 23, 2016; doi: 10.1158/1535-7163.MCT-15-0643 Abstract: The diagnosis, classification, and management of cancer are traditionally dictated by the site of tumor origin, for example, breast or lung, and by specific histologic subtypes of site-of-origin cancers (e.g., non-small cell versus small cell lung cancer). However, with the advent of sequencing technologies allowing for rapid, […]

CollabRx Chief Scientific Officer Smruti Vidwans presents poster describing Framework for Genomic Biomarker Actionability and Use in Clinical Decision Making at Molecular Med Tri-Con 2016

Smruti Vidwans, PhD presented the Framework for Genomic Biomarker Actionability and Use in Clinical Decision Making poster at the 2016 Molecular Medicine Tri Conference in Moscone North Convention Center, San Francisco, CA. Download PDF Publication Reference: Vidwans S. Framework for Genomic Biomarker Actionability and Use in Clinical Decision Making; Poster presented at: Molecular Medicine Tri-Conference […]

CollabRx apps discussed in the British Journal of Healthcare Computing

The CollabRx Colorectal Targeted Therapy App, and our relationship with CAP (The College of American Pathologists) is briefly described in the latest issue of the British Journal of Healthcare Computing. The article quotes the chief editor of the app, Dr Heinz-Josef Lenz, professor at the Keck School of Medicine, University of Southern California: “The Therapy […]

Cancer Commons Researchers Publish Molecular Disease Model for Lung Cancer

PALO ALTO, Calif.–(BUSINESS WIRE)–Cancer Commons, an open‐science initiative to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model (MDM) for lung cancer. The paper, by Lisandra West, Ravi Salgia, and others will appear in the February 21st issue of PLoS ONE.

Lung Cancer Molecular Disease Model Published in PLoS ONE

A team including leading lung cancer researchers, and CollabRx scientists, has just published a novel Lung Cancer Molecular Disease Model in PLoS ONE, a leading peer-reviewed open source journal. (

CollabRx Targeted Therapy Finder noted by FDA (Genome Web)

An article appearing in the Nov. 2, 2011 issue of Genome Web highlights the CollabRx Targeted Therapy Finders in the context of a discussion about the complexities of pre-screening regarding clinical trials for personalized (targeted) therapies.

CollabRx Scientists Jeff Shrager, Marty Tenenbaum, and Mike Travers Describe Cancer Commons in “Collaborative Computational Technologies for Biomedical Research”

Methods, Processes, and Tools for Collaboration “The time has come to fundamentally rethink how we handle the building of knowledge in biomedical sciences today. This book describes how the computational sciences have transformed into being a key knowledge broker, able to integrate and operate across divergent data types.”—Bryn Williams-Jones, Associate Research Fellow, Pfizer The pharmaceutical […]

PLoS ONE: A Melanoma Molecular Disease Model

Peer Reviewed Molecular Disease Models While advanced melanoma remains one of the most challenging cancers, recent developments in our understanding of the molecular drivers of this disease have uncovered exciting opportunities to guide personalized therapeutic decisions. Genetic analyses of melanoma have uncovered several key molecular pathways that are involved in disease onset and progression, as well as prognosis. […]